Inhibrx Biosciences, Inc. (INBX) Stock

Inhibrx Biosciences, Inc. (INBX) is a Healthcare stock trading at $92.75 (as of 2026-06-18), with a market capitalization of $1.53B and a trailing P/E of -11.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Valuation — source: SEC EDGAR (first-party)

Price	$92.75
Market Cap	$1.53B
P/E Ratio	-11.1
EV / EBITDA	-11.4
Price / Book	-64.94
Price / Sales	1050.80
DCF Value (model)	$-149.69
DCF Upside vs Price	-261.4%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$1.30M
Net Margin	-10773.5%
Return on Equity	618.9%
Debt / Equity	-8.32
Current Ratio	6.46
Revenue Growth (YoY)	550.0%
EPS Growth (YoY)	-107.9%
FCF Growth (YoY)	-34.1%

Financial Health — source: SEC EDGAR

Altman Z-Score

1.30 (distress)

Valuation vs Sector & Industry

Stock P/E	-11.1
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-152.9%
vs Industry	-164.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	PERCEPTIVE ADVISORS LLC ($96.99M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Mark Paul Lappe
Employees	156
Country	US
IPO Date	2024-06-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Savara Inc. (SVRA)
• Omeros Corporation (OMER)
• Amphastar Pharmaceuticals, Inc. (AMPH)
• Phathom Pharmaceuticals, Inc. (PHAT)
• ARS Pharmaceuticals, Inc. (SPRY)
• Iovance Biotherapeutics, Inc. (IOVA)
• Novavax, Inc. (NVAX)
• Sana Biotechnology, Inc. (SANA)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.